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Abstract: Mutation in the KRAS gene induces prominent metabolic changes. We have recently
reported that KRAS mutations in colorectal cancer (CRC) cause alterations in amino acid metabolism.
However, it remains to be investigated which amino acid transporter can be regulated by mutated
KRAS in CRC. Here, we performed a screening of amino acid transporters using quantitative
reverse-transcription polymerase chain reaction (RT-PCR) and then identified that ASCT2 (SLC1A5)
was up-regulated through KRAS signaling. Next, immunohistochemical analysis of 93 primary CRC
specimens revealed that there was a significant correlation between KRAS mutational status and
ASCT2 expression. In addition, the expression level of ASCT2 was significantly associated with
tumor depth and vascular invasion in KRAS-mutant CRC. Notably, significant growth suppression
and elevated apoptosis were observed in KRAS-mutant CRC cells upon SLC1A5-knockdown. ASCT2
is generally known to be a glutamine transporter. Interestingly, SLC1A5-knockdown exhibited a more
suppressive effect on cell growth than glutamine depletion. Furthermore, SLC1A5-knockdown also
resulted in the suppression of cell migration. These results indicated that ASCT2 (SLC1A5) could be a
novel therapeutic target against KRAS-mutant CRC.
Keywords: colorectal cancer; KRAS; ASCT2; SLC1A5
1. Introduction
Colorectal cancer (CRC) is one of the most common cancers worldwide; therefore, development
of novel diagnostic measures and treatment is very important [1]. KRAS mutations are found in
approximately 40% of CRC cases [2–4]. A number of clinical trials have shown that KRAS mutations
in CRC can predict a lack of responses towards anti-epidermal growth factor receptor (EGFR)-based
therapy [2–4]. Therefore, development of new therapy for CRC with mutated KRAS has been desired
clinically. Some studies have investigated the correlation between KRAS mutations and metabolic
alterations in pancreatic and lung cancers [5–9] as well as in CRC [10–15]. We have recently reported
that, using metabolome analysis, concentration of amino acids is elevated in CRC cells with mutated
KRAS compared to CRC cells with wild-type KRAS [12]. The increase in glucose transporter 1 (GLUT1)
expression and glucose uptake was critically dependent on mutated KRAS [16–18]. However, it
remains to be investigated which amino acid transporter is specifically regulated by mutated KRAS in
CRC. In the present study, we performed a screening of amino acid transporters in KRAS-mutant CRC
cells transfected by siKRAS and found that ASCT2 (SLC1A5) was particularly up-regulated through
KRAS signaling.
The SLC1A5 gene encodes alanine-serine-cysteine amino acid transporter (ASCT2), which is an
essential glutamine transporter. ASCT2 over-expression has been reported in several cancers [19–31].
Int. J. Mol. Sci. 2017, 18, 1632; doi:10.3390/ijms18081632 www.mdpi.com/journal/ijms
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However, the role of ASCT2 in CRC has not yet been reported. In addition to glucose, glutamine is an
essential source of cellular building blocks to fuel cell proliferation. Recent studies have established a
better understanding about the importance of glutamine as a critical nutrient in fast growing cancer
cells [32–34]. In the present study, we investigated the significance of ASCT2 expression in CRC using
in vitro cultures and clinical samples.
2. Results
2.1. SLC1A5 (ASCT2) Is Regulated through KRAS Signaling in KRAS-Mutant CRC Cells
We have recently reported that mutated KRAS induces metabolic alterations in many amino
acids [12]. Therefore, we hypothesized that the expression of amino acid transporters might be
regulated by mutated KRAS. Several amino acid transporters (SLC1A5, SLC7A5, SLC7A11, SLC3A2,
and SLC43A1) have been reported to be up-regulated in different cancers [32]. To determine the
specific transporter that could be regulated by mutated KRAS, we introduced two different small
interfering RNAs (siRNAs) targeting KRAS in KRAS-mutant CRC cell lines (HCT116 and DLD-1). We
confirmed that siKRAS significantly reduced the mRNA levels of KRAS in both cell lines (Figure S1a).
Interestingly, KRAS-knockdown significantly reduced SLC1A5 expression in both KRAS-mutant cell
lines (Figure 1a). SLC1A5 (ASCT2) is a known glutamine transporter. Next, we investigated whether
glutamine transporters other than SLC1A5 (i.e., SLC1A4, SLC38A1, SLC38A2, SLC38A3, and SLC38A5)
could be regulated by KRAS signaling [33]. Expression levels of SLC1A4 and SLC38A1 were decreased
after KRAS-knockdown in HCT116; however, their expression was not decreased in DLD-1 (Figure 1b).
We also found that KRAS-knockdown significantly reduced protein expression of ASCT2 in both
KRAS-mutant cell lines (Figure 1c). The mutated KRAS continuously activates both Raf/MEK/ERK
and PI3K/Akt/mTOR pathways. To investigate which pathway regulates ASCT2 expression, we
used specific inhibitors of each pathway. Western blot analysis revealed that ASCT2 expression was
dramatically reduced in KRAS-mutant CRC cell lines by addition of LY 294002 (PI3K inhibitor) or
rapamycin (mTOR inhibitor), which suggested that KRAS signaling may regulate ASCT2 expression
in CRC mainly via the PI3–Akt–mTOR pathway (Figure 1d).
2.2. Relationship between ASCT2 Expression and KRAS Mutational Status in CRC Clinical Samples
We next performed immunohistochemistry (IHC) to evaluate the relationship between ASCT2
expression and KRAS mutational status in clinical specimens of human primary CRC. Regarding the
expression levels of ASCT2, we classified the clinical specimens into four groups; score 0 (0–10%), score
1+ (10–40%), score 2+ (40–70%), and score 3+ (≥70%). Score 0 was found in 12 patients (12.9%), score
1+ in 22 patients (23.6%), score 2+ in 29 patients (31.2%), and score 3+ in 30 patients (32.3%) (Figure 2a).
We defined score 3+ as the high expression group, while score 0, 1+, and 2+ were categorized as the
low expression group. Regarding KRAS mutational status, mutated KRAS and wild-type KRAS were
found in 39 and 54 patients, respectively. ASCT2 expression was high in 43.6% (17 of 39) of CRC
patients with mutated KRAS, whereas in 24.1% (13 of 54) of CRC patients with wild-type KRAS, which
indicated that there was a significant correlation between high ASCT2 expression and KRAS mutation
(risk ratio: 1.62, 95%; confidence interval (CI): 1.02–2.57, p = 0.047, Figure 2b).
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Figure 1. Identification of the amino acid transporter regulated by mutated KRAS. (a) Relative mRNA 
levels of amino acid transporters that are reported to be associated with cancer; (b) relative mRNA 
levels of amino acid transporters that are involved in glutamine transport. HCT116 cells (left) and 
DLD-1 cells (right) were treated separately with two independent siRNA constructs (#1 and #2) 
targeting KRAS and negative control (NC) siRNA. Mean; bars, ± SD, n = 3 (Student’s t-test; * p < 0.05); 
(c) Western blotting for KRAS, ASCT2, and β-actin (Actin). The relative ASCT2 expression levels for 
three independent experiments are shown by quantitative analysis normalized to β-actin (Actin); (d) 
CRC cells (HCT116 and DLD-1) were treated with 0.1% dimethyl sulfoxide (DMSO), 20 μM U0126 
(MEK inhibitor), and 50 μM LY294002 (PI3K inhibitor) or 20 nM rapamycin (mTOR inhibitor) for 48 
h. Protein levels of ASCT2 were normalized to β-actin (Actin). Densitometry values were expressed 
as fold change compared with DMSO-treated cells. 
Figure 1. Identification of the amino acid transporter regulated by mutated KRAS. (a) Relative mRNA
levels i acid transporters that are reported to be associated with cancer; (b) relative mRNA levels
of amino acid transporter that are involv d in glutamine transport. HCT116 cells (left) and DLD-1 cells
(right) were treated separately with two independent siRNA constructs (#1 and #2) targeting KRAS and
ne ative control (NC) siRNA. Mean; bars, ± SD, n = 3 (Student’s t-test; * p < 0.05); (c) Western blotting
for KRAS, ASCT2, and β-actin (Actin). The relative ASCT2 expression levels for three independent
experiments are shown by quantitative analysis normalized to β-actin (Actin); (d) CRC cells (HCT116
and DLD-1) were treated with 0.1% dimethyl sulfoxide (DMSO), 20 µM U0126 (MEK inhibitor), and
50 µM LY294002 (PI3K inhibitor) or 20 nM rapamycin (mTOR inhibitor) for 48 h. Protein levels
of ASCT2 were normalized to β-actin (Actin). Densitometry values were expressed as fold change
compared with DMSO-treated cells.
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Figure 2. Immunohistochemical staining for ASCT2 of primary colorectal cancer (CRC) specimens. 
(a) Representative picture. Scale bar, 200 μm (200× magnification); (b) Relationship between KRAS 
mutational status and ASCT2 expression. 
2.3. Knockdown of SLC1A5 (ASCT2) Results in Suppression of Cell Growth 
To investigate the role of SLC1A5 (ASCT2) in CRC cell lines with mutated KRAS, we introduced 
non-silencing siRNA and two different siRNAs targeting SLC1A5 (referred as siSLC1A5#1 and 
siSLC1A5#2) into CRC cell lines (Figure S2). Knockdown of SLC1A5 (ASCT2) significantly suppressed 
the cell growth in all the 3 cell lines with mutated KRAS (HCT116, DLD-1, and SW480), whereas in 1 
out of 3 cell lines with wild-type KRAS (RKO) (Figure 3a). Furthermore, we investigated the 
knockdown effect of SLC1A5 on cell apoptosis. Knockdown of SLC1A5 induced a significant increase 
in caspase 3/7 activities in all the 3 cell lines with mutated KRAS (HCT116, DLD-1, and SW480), 
whereas in 2 out of 3 cell lines with wild-type KRAS (HT29 and RKO) (Figure 3b). Oncogenic PIK3CA 
mutations were reported to reprogram glutamine metabolism in CRC [35]. PIK3CA mutations are 
observed in HCT116 (a H1047R mutation), DLD-1 (E545K; D549N mutations), HT29 (a P449T 
mutation), WiDR (a P449T mutation), and RKO (a H1047R mutation), whereas the PIK3CA status is 
wild-type in SW480. The PIK3CA status might be related to the differences in the knockdown effect 
of SLC1A5 between cell lines. 
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2.3. Knockdo n of SLC1A5 (ASCT2) Results in Suppres ion of Cel Growth
To investigate the role of SLC1A5 (ASCT2) in CRC cel lines with utated KRAS, e introduced
non-silencing siR and t o dif erent siRNAs targeting SLC1A5 (refer ed as siSLC1A5#1 and
siSLC1A5#2) into CRC cel lines (Figure S2). c o n f 5 ( 2) si ificantly s ppressed
the cel growth in all the 3 cell ines with mutated KRAS (HCT116, DL -1, and SW480), whereas in 1 out
of 3 cell lines with wild-type KRAS (R O) (Figure 3a). Furthermore, we investigated the knockdown
effect of SLC1A5 on cell apopt sis. Knockdown of SLC1A5 induced a signifi ant increase in caspase
3/7 ctivities in all the 3 cell lines with mutated KRAS (HCT116, DLD-1, and SW480), whereas in 2
out of 3 cell lines with wi d-type KRAS (HT29 and RKO) (Figure 3b). Oncogenic PIK3CA mutations
were reported to rogram glutamine metabolism in CRC [35]. PIK3CA mutations are observed in
HCT116 (a H1047R mutation), DLD-1 (E545K; D549N mutations), HT29 (a P449T mutation), WiDR (a
P449T mutation), and RKO (a H1047R mutation), whereas the PIK3CA status i wild-type in SW480.
The PIK3CA status might be related to the differ nces in the knockdown effec of SLC1A5 betwe n
cell lines.
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Figure 3. SLC1A5 knockdown inhibits cell proliferation and induces cell apoptosis of CRC cells. (a) 
Cell proliferation measured by CCK-8 assay. CRC cells were transfected with negative control (NC) 
or two independent siSLC1A5 and cultured for 72 h. Viability in each siSLC1A5 was normalized to 
that in NC. Student’s t-test; * p < 0.05; (b) caspase 3/7 activities measured by Caspase-Glo assay. CRC 
cells transfected with negative control (NC) or two independent siSLC1A5 were cultured for 72 h. 
Caspase 3/7 activity was normalized to the cell viability measured by CCK-8 assay under the same 
density and conditions. Mean; bars, ± SD, n = 3 (Student’s t-test; * p < 0.05). 
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suppressed colony number as compared to the control (Figure 4c). Moreover, in the wound healing
assay, SLC1A5-knockdown significantly inhibited wound closure as compared to the control (Figure 4d).
Taken together, these results indicate that the inhibition of SLC1A5 (ASCT2) could be a therapeutic
target in KRAS-mutant CRC.
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2.5. Tumor Characteristics and ASCT2 Expression in CR linical Sa ples
Table 1 shows the relationship between ASCT2 expression and clinicopathologic variables. ASCT2
expression was significantly correlated with tumor location, but not with age, sex, tumor size, stage,
T-/N-/M-category, lymphatic invasion, or vascular invasion. We further investigated the clinical
significance of ASCT2, based on the KRAS mutational status. Interestingly, we found that high ASCT2
expression was significantly associated with tumor depth and vascular invasion in KRAS-mutant CRC,
which was not observed in wild-type KRAS CRC.
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Table 1. Correlation between ASCT2 expression and clinicopathological variables (* p < 0.05).
Variables
Total KRAS Wild-Type KRAS Mutant
ASCT2 ASCT2 ASCT2
High (n = 30) Low (n = 63) p-value High (n = 13) Low (n = 41) p-value High (n = 17) Low (n = 22) p-value
Age, mean ± SD (y) 71.2 ± 9.4 68.0 ± 10.7 0.16 69.8 ± 10.5 67.2 ± 10.6 0.42 72.2 ± 9.8 69.4 ± 11.1 0.41
Sex
Male 16 39 0.43 8 28 0.65 8 11 0.86
Female 14 24 5 13 9 11
Location
Left 18 50 0.049 * 9 33 0.45 9 17 0.11
Right 12 13 4 8 8 5
Tumor size (mm)
≥50 12 25 0.98 5 15 0.9 12 25 0.98
<50 18 38 8 26 18 38
UICC-TMN stage
I/II 14 33 0.61 7 23 0.89 7 10 0.79
III/IV 16 30 6 18 10 12
T-category
1/2 5 25 0.16 4 10 0.72 1 9 0.024 *
3/4 25 44 9 31 16 13
M-category
Negative 25 53 0.92 10 35 0.67 15 18 0.75
Positive 5 10 3 6 2 4
N-category
Negative 16 35 0.84 8 23 0.73 8 12 0.64
Positive 14 28 5 18 9 10
Lymphatic invasion
Negative 18 39 0.86 6 25 0.35 12 14 0.65
Positive 12 24 7 16 5 8
Vascular invasion
Negative 6 19 0.3 3 8 1 3 11 0.049 *
Positive 24 44 10 33 14 11
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2.6. Patients’ Prognosis
To evaluate the relationship between ASCT2 expression and patients’ prognosis, we performed
the log-rank test analysis with CRC patients who underwent curative resection of primary CRC (n = 90).
Kaplan–Meier survival curves indicated that ASCT2 expression was not significantly correlated with
recurrence-free survival (RFS) in all cases (Figure 5a). However, in KRAS-mutant CRC cases (n = 38),
the estimated RFS rate at 5-year tended to be lower in the high ASCT2 group than in the low ASCT2
group (52.9% vs. 70.2%; p = 0.251) (Figure 5b, right). On the other hand, in wild-type KRAS CRC cases
(n = 52), the estimated RFS rate at 5-year was almost similar between the high and low ASCT2 groups
(84.6% vs. 75.8%; p = 0.513) (Figure 5b, left). Taken together, high ASCT2 expression can be one of the
crucial prognostic factors in KRAS-mutant CRC.
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and fatty acids. The mechanism by which mutated KRAS coordinates the metabolic reprogramming
to promote tumor growth remains to be investigated. The International CRC Subtyping Consortium
has suggested that CRC can be divided into four subtypes with distinguished features: CMS1, CMS2,
CMS3, and CMS4 [15]. Notably, CMS3 is characterized by metabolic dysregulation and is strongly
associated with KRAS mutations. Using a comprehensive metabolomics analysis with isogenic CRC
cell lines harboring mutated or wild-type KRAS, we have recently reported that mutated KRAS induces
some metabolic alterations in glycolysis, the pentose phosphate pathway (PPP), the tricarboxylic
acid (TCA) cycle, and most significantly in the amino acid pathway [12]. We identified that mutated
KRAS regulated asparagine synthetase (ASNS), an enzyme that is involved in de novo synthesis of
asparagine from aspartate, and that KRAS-mutant CRC cells could become adaptive to glutamine
depletion through ASNS-dependent asparagine biosynthesis. There is also some evidence from
other groups that KRAS mutations in CRC are associated with glutamine metabolism. Wong et al.
reported that SLC25A22 (a mitochondrial glutamine transporter) was a synthetic lethal metabolic
gene in KRAS-mutant CRC cells and that expression of SLC25A22 was correlated with poor prognosis
in patients harboring KRAS mutations [11]. Miyo et al. reported that glutamine dehydrogenase 1
(GLUD1) and SLC25A13 (a mitochondrial aspartate-glutamate carrier) played an essential role in cell
survival of CRC cells under glucose-deprived conditions, and that combined expression of GLUD1
and SLC25A13 was significantly associated with tumor aggressiveness and poorer prognosis in CRC
patients [13]. These results indicate that the amino acid metabolism including glutaminolysis is more
essential for cell survival in KRAS-mutant CRC than in wild-type KRAS CRC.
In this study, we focused on the amino acid transporter which was exclusively regulated by
mutated KRAS, although several amino acid transporters have been reported to be up-regulated in
cancer [32]. Herein, we identified SLC1A5 as a novel target gene regulated by mutated KRAS in CRC.
Expressions of SLC25A22 and SLC25A13 were not affected by KRAS-knockdown in our experiments
(Figure S1b). Up-regulation of SLC1A5 (ASCT2) and its clinical significance has been reported in
a variety of human cancers [19–31]. In the present study, we demonstrated that SLC1A5 (ASCT2)
expression was regulated through KRAS signaling, and that SLC1A5-knockdown resulted in reduced
cell growth and increased cell apoptosis in KRAS-mutant CRC cells (Figures 1 and 3). Importantly, the
effect of SLC1A5-knockdown was more prominent on cell growth and apoptosis than that of glutamine
depletion (Figure 4a,b), which indicates that SLC1A5 (ASCT2) plays a critical role in the malignant
progression of KRAS-mutant CRC. Furthermore, SLC1A5-knockdown resulted in the suppression of
cell migration (Figure 4d). In primary CRC clinical specimens, we found that ASCT2 expression was
significantly associated with tumor depth and vascular invasion in KRAS-mutant CRC, but not in
wild-type KRAS CRC (Table 1). In conclusion, our data indicates that SLC1A5 (ASCT2) could be a
novel biomarker as well as a potential therapeutic target in KRAS-mutant CRC.
4. Materials and Methods
4.1. Cell Lines and Reagents
HCT116, DLD-1, SW480, SW620, HT29, RKO, and WiDR cells were obtained from American
Type Culture Collection. All cell lines were cultured in Dulbecco’s Modified Eagle Medium (DMEM)
(glucose 25 mM, glutamine 4 mM) (043-30085, Wako, Tokyo, Japan) supplemented with 10% FBS and
penicillin–streptomycin. Media without glutamine were prepared by using glutamine-free DMEM
(glucose 25 mM, glutamine 0 mM) (045-32245, Wako) supplemented with 10% FBS. The identity of
each cell line was confirmed by STR analysis (Takara Bio, Shiga, Japan). U0126 was purchased from
Calbiochem, LY294002 and rapamycin were from Wako.
4.2. Quantitative Reverse Transcription Polymerase Chain Reaction (RT-PCR) Analysis
Total RNAs were extracted from cells with High Pure RNA Isolation Kit (Roche, Mannheim,
Germany) according to the manufacturer’s instructions. RNA was reverse transcribed to cDNA with
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Transcriptor First Strand cDNA Synthesis Kit (Roche) according to the manufacturer’s instructions.
The relative levels of respective genes were quantified using StepOnePlusTM Real-Time PCR System
(Applied Biosystems, Foster City, CA, USA). The respective mRNA levels were normalized to that for
ACTB. Primer sequences were found in Table S1.
4.3. Western Blot Analysis
Cells were washed with ice-cold phosphate-buffered saline and lysed in sodium dodecyl sulfate
lysis buffer supplemented with inhibitor cocktails of protease and phosphatase. Primary antibodies
can be found in Table S2.
4.4. Small Interfering RNA and Short Hairpin RNA
FlexiTube GeneSolutions for siSLC1A5 (#1: SI05141017, #2: SI00079730) and non-silencing control
siRNA (AllStars negative control siRNA, SI03650318) were purchased from Qiagen (Hilden, Germany).
The siRNA (10 nM) was transfected with Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA, USA)
according to the manufacturer’s reverse-transfection protocol. SLC1A5 shRNA vectors were made
from the same sequence of siSLC1A5 (#1, #2), and cloned into pLKO.1 vectors. pLKO.1-scramble vector
(Addgene) was used as control.
4.5. Cell Proliferation Assay
A cell proliferation assay was measured by Cell Counting Kit-8 (Dojindo, Kumamoto, Japan)
according to the manufacturer’s instruction. Cells transfected with siRNA were cultured in 96-well
plates at a density of 5000 cells/well for 72 h.
4.6. Clonogenic Assay
Cells were seeded in 6-well plates at a density of 100 cells per well in complete media. At the end
point, colonies were fixed in 1% glutaraldehyde and stained with 0.2% crystal violet for 30 min, and
number of colonies was counted. A colony was defined as a cluster of at least 50 cells.
4.7. Apoptosis Assay
The activity of Caspase-3 and -7 was measured by using Caspase-Glo 3/7 assay (Promega,
Madison, WI, USA) according to the manufacturer’s protocol. Caspase activity was normalized to the
cell number counted by CCK-8 cell proliferation assay under the same density and conditions.
4.8. Wound Healing Assay
Cell lines were seeded into 12-well plates and grew until 80–90% confluence. Confluent cultures
were scratched with sterile tips, washed with PBS, and cultured in DMEM containing 5% FBS. Cells
were photographed by a 50× magnification at 0, 24, and 48 h. Wound closure (%) was evaluated using
the ImageJ software.
4.9. Immunohistochemistry
Formalin-fixed, paraffin-embedded sections were stained with anti-rabbit ASCT2 (Sigma-Aldrich,
St. Louis, MO, USA) antibody. Antigen retrieval was achieved with microwave in citrate buffer (pH:
6.0). For primary CRC tissue, ASCT2 immunoreactivity score was determined by the proportion, as
previously described [30]. The proportion was scored based on the positively rate as “0” (0–10%), “1”
(10–40%), “2” (40–70%), “3” (>70%). Scores of 0, 1, and 2 were defined as low expression, whereas 3
was high expression.
Two researchers (Kosuke Toda and Gen Nishikawa) independently evaluated all
immunohistochemistry samples without prior knowledge of other data. The slides with different
evaluations among them were reinterpreted at a conference to reach the consensus.
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4.10. Patients, Clinicopathological Data
93 patients were collected from patients who underwent primary colorectal cancer resection at
Kyoto University Hospital between April 2009 and September 2013.
No patients received chemotherapy and/or radiation therapy. KRAS mutational status in all
patients was analyzed by using an ABI 3130 Genetic Analyzer (Applied Biosystems, foster City, CA,
USA), as described previously. Pathologic staging was categorized in accordance with the 7th edition
of Union for International Cancer Control (UICC) classification of malignant tumors.
4.11. Statistical Analysis
All values were expressed as mean± standard deviation (SD). Statistical analyses were conducted
with the JMP Pro 12 (SAS Institute, Inc., Cary, NC, USA). Student’s t-test was used for comparing
means between two groups. In clinical data, the statistical significance of differences between variables
of two groups was determined by student’s t-test, chi-squared test, or Fisher’s exact test. Relapse-free
survival (RFS) rates were evaluated by the Kaplan–Meier survival curve and log-rank test. All analyses
were two-sided, and differences with a p value of less than 0.05 were considered statistically significant
in all analyses.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/18/8/1632/s1.
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ASCT2 Alanine-serine-cysteine amino acid transporter
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